Merck and Isomorphic Labs, the artificial intelligence drug designer built on a Nobel winning technology that can model how molecules will bind to proteins, said Thursday that they are entering into a research collaboration to discover small molecule candidates for an undisclosed oncology target of “strategic importance.” The partnership — only the latest such deal between a pharma giant and Isomorphic — will bring together the latter’s proprietary drug design engine and existing wet lab data from Merck, officials from both companies said. Merck will handle the preclinical and clinical development, manufacturing, and commercializing of any products. “It is a target of high interest to us, a target where we have deployed internal efforts, and we think the pairing of those datasets with the Isomorphic drug discovery engine technology could be a very powerful pairing,” said George Addona, global head of discovery, preclinical development, and translational medicine at Merck. The aim is to use Isomorphic’s modeling and compute capabilities to expedite the discovery process. “At the end of the day, the ability for us to identify new ways to discover better molecules faster is truly, truly exciting,” Addona said. Under the agreement, Isomorphic will receive an undisclosed upfront payment and is eligible for later payments tied to research, development, regulatory, and commercial milestones, as well as tiered royalties on net sales. Isomorphic also has the option to co-fund development activities for higher royalties. The announcement comes days after Isomorphic announced it had raised $5 billion in additional private funding, and six months after having raised $2.1 billion. Its other pharma industry research partners include Novartis, Eli Lilly, and Johnson & Johnson. While Isomorphic has its own internal drug development program, broadening its reach through external partnerships is a critical part of its strategy, according to the company’s chief research officer, Sarah Skerratt. “We always say that we’re here to ‘solve all disease,’ but we’re not going to do that in isolation. … The only way we’re going to solve our mission is to have partners that can enable that journey with us,” Skerratt said. For Adonna, the partnership reflects how quickly AI is maturing — a sign that the technology is being used “in ways that we could only have dreamed of a few years ago,” he said. Isomorphic, which spun out from Google’s DeepMind in 2021 and is now based in London, is best known for the development of AlphaFold, an open-access AI program that predicts the 3D structures of proteins from their amino acid sequences. This year, Isomorphic released its proprietary commercial platform for drug developers, called Isomorphic Labs Drug Design Engine. The IsoDDE system is intended to tackle some of drug design’s toughest challenges, like discovering hidden pockets on proteins and estimating how strongly a molecule can bind to its target. Isomorphic’s founder and CEO, Demis Hassabis, was awarded the 2024 Nobel Prize in chemistry for developing the AlphaFold model.
Merck, Isomorphic Labs partner to develop oncology drug candidates
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.